Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A compassionate access program assessing the combination of Veyonda with 177Lu-PSMA therapy for patients with advanced, treatment resistant, metastatic prostate cancer (mCRPC) being treated with theranostics

Next Previous
Trial Profile

A compassionate access program assessing the combination of Veyonda with 177Lu-PSMA therapy for patients with advanced, treatment resistant, metastatic prostate cancer (mCRPC) being treated with theranostics

Status: Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 07 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idronoxil (Primary) ; Lutetium (177Lu) vipivotide tetraxetan (Primary)
  • Indications Prostate cancer
  • Focus Expanded access; Therapeutic Use
  • Sponsors Noxopharm

    • Most Recent Events

    • 30 Jun 2022 Status changed from suspended to planning, According to a Novartis media release.
    • 30 Jun 2022 According to Novartis media release, company has remediated the issues that led to the temporary, voluntary suspension. These issues did not affect patient safety, and no risk to patients from the doses previously produced at these sites was identified.Company restarted screening and enrollment for clinical trials with 177Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan) in the US, in most countries globally.
    • 05 May 2022 According to Novartis media release, Novartis is putting a temporary hold on screening and enrollment for 177Lu-PSMA-617 clinical trials globally, hence status changed to suspended.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top